847 related articles for article (PubMed ID: 20635188)
1. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.
Tzur S; Rosset S; Shemer R; Yudkovsky G; Selig S; Tarekegn A; Bekele E; Bradman N; Wasser WG; Behar DM; Skorecki K
Hum Genet; 2010 Sep; 128(3):345-50. PubMed ID: 20635188
[TBL] [Abstract][Full Text] [Related]
2. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
[TBL] [Abstract][Full Text] [Related]
3. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.
Freedman BI; Kopp JB; Langefeld CD; Genovese G; Friedman DJ; Nelson GW; Winkler CA; Bowden DW; Pollak MR
J Am Soc Nephrol; 2010 Sep; 21(9):1422-6. PubMed ID: 20688934
[TBL] [Abstract][Full Text] [Related]
4. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15.
Nelson GW; Freedman BI; Bowden DW; Langefeld CD; An P; Hicks PJ; Bostrom MA; Johnson RC; Kopp JB; Winkler CA
Hum Mol Genet; 2010 May; 19(9):1805-15. PubMed ID: 20124285
[TBL] [Abstract][Full Text] [Related]
5. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans.
Behar DM; Rosset S; Tzur S; Selig S; Yudkovsky G; Bercovici S; Kopp JB; Winkler CA; Nelson GW; Wasser WG; Skorecki K
Hum Mol Genet; 2010 May; 19(9):1816-27. PubMed ID: 20144966
[TBL] [Abstract][Full Text] [Related]
6. MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing?
Kopp JB; Winkler CA; Nelson GW
Semin Nephrol; 2010 Jul; 30(4):409-17. PubMed ID: 20807613
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
Freedman BI; Langefeld CD; Lu L; Divers J; Comeau ME; Kopp JB; Winkler CA; Nelson GW; Johnson RC; Palmer ND; Hicks PJ; Bostrom MA; Cooke JN; McDonough CW; Bowden DW
PLoS Genet; 2011 Jun; 7(6):e1002150. PubMed ID: 21698141
[TBL] [Abstract][Full Text] [Related]
8. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.
Papeta N; Kiryluk K; Patel A; Sterken R; Kacak N; Snyder HJ; Imus PH; Mhatre AN; Lawani AK; Julian BA; Wyatt RJ; Novak J; Wyatt CM; Ross MJ; Winston JA; Klotman ME; Cohen DJ; Appel GB; D'Agati VD; Klotman PE; Gharavi AG
J Am Soc Nephrol; 2011 Nov; 22(11):1991-6. PubMed ID: 21997397
[TBL] [Abstract][Full Text] [Related]
9. In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress.
Anderson BR; Howell DN; Soldano K; Garrett ME; Katsanis N; Telen MJ; Davis EE; Ashley-Koch AE
PLoS Genet; 2015 Jul; 11(7):e1005349. PubMed ID: 26147622
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease.
Palmer ND; Ng MC; Hicks PJ; Mudgal P; Langefeld CD; Freedman BI; Bowden DW
PLoS One; 2014; 9(2):e88273. PubMed ID: 24551085
[TBL] [Abstract][Full Text] [Related]
11. Association of trypanolytic ApoL1 variants with kidney disease in African Americans.
Genovese G; Friedman DJ; Ross MD; Lecordier L; Uzureau P; Freedman BI; Bowden DW; Langefeld CD; Oleksyk TK; Uscinski Knob AL; Bernhardy AJ; Hicks PJ; Nelson GW; Vanhollebeke B; Winkler CA; Kopp JB; Pays E; Pollak MR
Science; 2010 Aug; 329(5993):841-5. PubMed ID: 20647424
[TBL] [Abstract][Full Text] [Related]
12. MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population.
Colares VS; Titan SM; Pereira Ada C; Malafronte P; Cardena MM; Santos S; Santos PC; Fridman C; Barros RT; Woronik V
PLoS One; 2014; 9(3):e87716. PubMed ID: 24658608
[TBL] [Abstract][Full Text] [Related]
13. MYH9 and APOL1 are both associated with sickle cell disease nephropathy.
Ashley-Koch AE; Okocha EC; Garrett ME; Soldano K; De Castro LM; Jonassaint JC; Orringer EP; Eckman JR; Telen MJ
Br J Haematol; 2011 Nov; 155(3):386-94. PubMed ID: 21910715
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in APOL1 and MYH9 genes is associated with chronic kidney disease among Nigerians.
Tayo BO; Kramer H; Salako BL; Gottesman O; McKenzie CA; Ogunniyi A; Bottinger EP; Cooper RS
Int Urol Nephrol; 2013 Apr; 45(2):485-94. PubMed ID: 22956460
[TBL] [Abstract][Full Text] [Related]
15. The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus.
Rosset S; Tzur S; Behar DM; Wasser WG; Skorecki K
Nat Rev Nephrol; 2011 Jun; 7(6):313-26. PubMed ID: 21537348
[TBL] [Abstract][Full Text] [Related]
16. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.
Genovese G; Tonna SJ; Knob AU; Appel GB; Katz A; Bernhardy AJ; Needham AW; Lazarus R; Pollak MR
Kidney Int; 2010 Oct; 78(7):698-704. PubMed ID: 20668430
[TBL] [Abstract][Full Text] [Related]
17. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.
Hicks PJ; Langefeld CD; Lu L; Bleyer AJ; Divers J; Nachman PH; Derebail VK; Bowden DW; Freedman BI
Kidney Int; 2011 Dec; 80(12):1339-43. PubMed ID: 21849968
[TBL] [Abstract][Full Text] [Related]
18. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis.
Lin CP; Adrianto I; Lessard CJ; Kelly JA; Kaufman KM; Guthridge JM; Freedman BI; Anaya JM; Alarcón-Riquelme ME; ; Pons-Estel BA; Martin J; Glenn S; Adler A; Bae SC; Park SY; Bang SY; Song YW; Boackle SA; Brown EE; Edberg JC; Alarcón GS; Petri MA; Criswell LA; Ramsey-Goldman R; Reveille JD; Vila LM; Gilkeson GS; Kamen DL; Ziegler J; Jacob CO; Rasmussen A; James JA; Kimberly RP; Merrill JT; Niewold TB; Scofield RH; Stevens AM; Tsao BP; Vyse TJ; Langefeld CD; Moser KL; Harley JB; Gaffney PM; Montgomery CG
Genes Immun; 2012 Apr; 13(3):232-8. PubMed ID: 22189356
[TBL] [Abstract][Full Text] [Related]
19. Target organ damage in African American hypertension: role of APOL1.
Freedman BI; Murea M
Curr Hypertens Rep; 2012 Feb; 14(1):21-8. PubMed ID: 22068337
[TBL] [Abstract][Full Text] [Related]
20. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.
Kopp JB; Smith MW; Nelson GW; Johnson RC; Freedman BI; Bowden DW; Oleksyk T; McKenzie LM; Kajiyama H; Ahuja TS; Berns JS; Briggs W; Cho ME; Dart RA; Kimmel PL; Korbet SM; Michel DM; Mokrzycki MH; Schelling JR; Simon E; Trachtman H; Vlahov D; Winkler CA
Nat Genet; 2008 Oct; 40(10):1175-84. PubMed ID: 18794856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
